In fact, these findings not only generated interest in the use of CDK4/6i in HER2+BC therapy, but they also demonstrated that the simultaneous treatment of HER2 targeted drugs and CDK4/6i is effective, and these two inhibitors may work well in combination. Here, CDK4 is linked to breast cancer.